格隆汇2月16日丨北海康成-B(01228.HK)发布公告，2026年2月15日，公司与认购人(即WuXi Biologics HealthCare Venture，为药明生物(02269.HK)的间接全资附属公司)订立认购协议，据此，公司已有条件同意发行及认购人已有条件同意认购合共8403.36万股认购股份，认购价为每股认购股份2.38港元。认购事项项下的认购股份相当于本公告日期现有已发行股份数目约16.44%。 认购事项所得款项总额将约为2亿港元，公司根据认购事项应收所得款项净额估计约为1.99亿港元。公司拟将认购事项所得款项净额用于(i)商业化产品的营运资金及注册维护；(ii)现有产品线的研发开支；及(iii)结算集团的贸易应付款项。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.